Background Introduction

Lung cancer is the malignant tumor serious posing severe threat to national health, and its mortality ranks first among all malignant tumors. In the face of high mortality, early diagnosis and treatment have become the key to improving the overall prognosis of lung cancer patients. 

Lung cancer is usually divided into two types, Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). SCLC accounts for 15-20% of the total number of new lung cancer in which it shows an upward trend in recent years. NSCLC has early symptoms and is easier to be found. Early surgical treatment has a high cure rate. In contrast, SCLC has hidden onset, rapid growth, easy and early metastasis, and high malignancy. When patients show symptoms, most of them are in late stage, and the 5-year survival rate is low. SCLC is sensitive to radiotherapy and chemotherapy. The complete remission rate can reach 50%~85% especially in early intensive treatment, but the secondary drug resistance is easy to recur. Therefore, SCLC is a cancer that needs early detection and treatment. Pro-Gastrin-Releasing Peptide (Pro-GRP) is a specific tumor marker of Small Cell Lung Cancer (SCLC). It has been used for early diagnosis, curative effect evaluation, disease monitoring and prognosis evaluation of small cell lung cancer in recent two years. Pro-GRP has important clinical significance for auxiliary diagnosis of Small Cell Lung Cancer. 

Recommended Diagnostic Raw Materials

[Product Information]

[Product Advantages]  

★Wide Linear Range

★High clinical detection agreement rate compared with that of product from R Company renowned internationally

[Product Performance]

Linear Range

On the chemiluminescence platform, Pro-GRP chemiluminescence microplate was used to detect the concentration of control materials, and the linear correlation is high within the concentration range of 0pg/ml to 5000pg/ml with R²＞ 0.99.

Clinical Agreement

On the chemiluminescence platform, Pro-GRP was prepared with paired antibody to detect the clinical serum assigned by R company renowned internationally. The sample agreement was R2 >0.98.

[Company Background]

Qingdao Henderson Biotechnology Co., Ltd, established in 2016, serves as a professional supplier of core raw materials for in vitro diagnostic reagents and is committed to providing high-quality raw materials for global in vitro diagnostic reagent production enterprises, scientific research institutions and other fields.

The company provides the following staple products: antigens, antibodies, enzymes, etc., widely used in the detection of drug, respiratory infectious diseases (A, B, COVID-19 antigen, COVID-19 antibody, COVID-19 neutralizing antibody, syncytial virus, etc.), other infectious diseases (hepatitis, AIDS, tuberculosis, etc.), markers for tumor, inflammation, myocardial markers, animal diseases detection (dog, cat diseases) and other fields. 

The company, after years of development, has established several specialized laboratories and SPF experimental animal bases, a comprehensive and systematic R&D verification platform and formed a professional technical service team to provide personalized customized services and one-stop solutions.

Qingdao Henderson Biotechnology Co., Ltd is willing to build a renowned product brand for all customers with high-quality products and professional services to keep a foothold in the market with its sound competitiveness.

Limited space only allows the introduction of major products. You are welcomed to contact Qingdao Henderson Biotechnology Co., Ltd and acquire trial samples if you need more information.

Qingdao Henderson Biotechnology Co., Ltd.

Official Website: http://www.qdhenderson.com/

Tel: 0532-84670782

E-mail: info@qdhenderson.com